<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03361202</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIO-01-2015</org_study_id>
    <nct_id>NCT03361202</nct_id>
  </id_info>
  <brief_title>Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium</brief_title>
  <acronym>MICROPLUG</acronym>
  <official_title>Evolution of Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium With Prosthesis (Amplatzer® Cardiac Plug)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Mutualiste Montsouris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société Française de Cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Mutualiste Montsouris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare levels of differnts types of microparticles circulating
      before and after percutaneous occluding of the left atrium by patients with atrial
      fibrillation and patients control.

      Hypothesis is that prothesis implantation will decrease levels of microparticles circulating
      in blood circulation because of occluding of the left atrium .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>levels of microparticles expressing phosphatidylserine in atrial fibrillation group</measure>
    <time_frame>45 days after Percutaneous Occluding of the Left Atrium.</time_frame>
    <description>blood samples analized by flow cytometry</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial fibrillation group</arm_group_label>
    <description>blood sampling</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>blood sampling</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up
control group:before coronary angiography and at hospital discharge.</description>
    <arm_group_label>Atrial fibrillation group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4 ml of arterial or venous blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        two groups of patients:

          -  control

          -  atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        atrial fibrillation group:

          -  high embolic risk (CHADS-VASC2 score ≥4)

          -  formal and final contraindication to anticoagulant therapy

          -  no heart thrombus on ETO and TDM before percuraneous occluding

        control group:

          -  suspicion of stable coronary artery disease, coronary angiography scheduled and double
             platelet aggregation (clopidogrel and aspirine)

        Exclusion Criteria: for both groups

          -  congestive heart failure, severe aortic stenosis, EP or TVP early.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas AMABILE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Mutualiste Montsouris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas AMABILE, doctor</last_name>
    <phone>+33 1 56 61</phone>
    <email>nicolas.amabile@imm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle SAURET</last_name>
    <phone>+33 1 56 61 67 05</phone>
    <email>isabelle.sauret@imm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2017</study_first_posted>
  <last_update_submitted>December 1, 2017</last_update_submitted>
  <last_update_submitted_qc>December 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

